Jared Kaltwasser

Serial biopsies help explain why patients with late relapses of diffuse large B-cell lymphoma (DLBCL) fare better than those with early relapses.

The therapy is still not widely used among older patients who have diffuse large B-cell lymphoma (DLBCL).

More data are needed to confirm the findings and assess individual risk levels, the authors said.

The patient was put on chemotherapy, but then underwent surgical resection following an accident at home.

Investigators say their data show the importance of vaccination and antibiotic stewardship programs.

A new review outlines strategies that may help reduce the risk of severe cytokine release syndrome (CRS) for patients treated with immunotherapy.

Shifts in clinical treatment patterns could prompt investigators to revisit the cost-effectiveness question.

Considering the depth and durability of responses with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL), the investigators added that CAR T cells should no longer be seen as a therapy only for heavily pretreated patients, but also as an option for earlier lines of therapy.

Data presented at the 2023 European Hematology Association Annual Meeting showed positive outcomes in patients with follicular lymphoma and large B-cell lymphoma, and further evaluation in diffuse large B-cell lymphoma is ongoing.

Investigators found important differences that may help clinicians better understand how to manage toxicities associated with the therapy.

The findings, which suggest that axicabtagene ciloleucel (axi-cel) may be a good option for a patient group often deemed ineligible for other curative-intent therapy, come from a planned subgroup analysis from the ZUMA-7 trial.

At a median follow-up of 10.7 months, the overall response rate was 63.1%.

The risk of CDI increased at a tertiary hospital, but not at the 2 community hospitals included in the study.

The case report highlights the importance of considering diffuse large B-cell lymphoma (DLBCL) when evaluating patients with persistent periaortic fluid collections.

Randomized controlled trials had lower rates of success, but microbiota restoration still out-performed antibiotics.

Moving to co-administration could also help more adults catch up with vaccination recommendations, the authors said.

Hospitals with the highest work-environment scores were less likely to have above-average Clostridioides difficile infection (CDI) rates.

Both complement inhibitors and neonatal Fc receptor blockers led to improvements in symptoms, according to a meta-analysis.

New therapies could potentially target immune systems at play in certain types of diffuse large B-cell lymphoma.

The scale is meant to better quantify how clusters of symptoms impact patients’ quality of life.

Physicians should proactively ask patients what alternative therapies, if any, they are using.

In some cases, individuals of Puerto Rican descent face lower risk than other Hispanic groups in the United States.

However, Clostridioides difficile (CDI) infection did not appear to affect outcomes, according to the study.

Investigators said longer-term outcomes from chimeric antigen receptor (CAR) T-cell therapies are still a significant question in patients who have non-Hodgkin lymphoma (NHL) or acute lymphoblastic leukemia (ALL).

Although acne and rosacea treatment are widely covered, treatment for other types of skin conditions are not covered at all, a new report shows.

Patients who have pulmonary arterial hypertension (PAH) often do not feel better after treatment, even if they meet clinical endpoints for improvement.

The majority of respondents living with generalized myasthenia gravis (MG) were not working, the results showed.

Two studies, one of zanubrutinib alone and one that combined the therapy with tislelizumab, showed promising results in a subset of patients.

Investigators said disease-modifying therapies may change the treatment landscape of sickle cell disease (SCD).

A new small case series finds higher rates of symptom flares in individuals who have muscle-specific tyrosine kinase (MuSK)–positive myasthenia gravis (MG) than previous research.